NewEdge Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

NewEdge Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-225	Closed	-$10.6K	–	4241
2025 Q2	$10.6K	Hold	225	–	–	﹤0.01%	3199
2025 Q1	$9.93K	Sell	225 -103	-31%	-$4.74K	﹤0.01%	3105
2024 Q4	$11.8K	Hold	328	–	–	﹤0.01%	2981
2024 Q3	$10.5K	Hold	328	–	–	﹤0.01%	2924
2024 Q2	$12.4K	Buy	328 +100	+44%	+$4.21K	﹤0.01%	2780
2024 Q1	$11.2K	Sell	228 -24	-10%	-$1.11K	﹤0.01%	2832
2023 Q4	$9.2K	Buy	+252	New	+$6.58K	﹤0.01%	2891
2023 Q1	–	Sell	-18	Closed	-$468	–	4081
2022 Q4	$468	Buy	+18	New	+$444	﹤0.01%	3183

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

NewEdge Advisors's SWTX Position: Q3 2025 in Review

NewEdge Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 225 shares — an estimated $10.6K sold.

NewEdge Advisors first reported a position in SWTX in Q4 2022 and held it in 8 quarters. The position peaked at $12.4K in Q2 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

NewEdge Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 225 SpringWorks Therapeutics shares in Q3 2025, an estimated $10.6K.
NewEdge Advisors first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 8 quarters.
NewEdge Advisors's SpringWorks Therapeutics position peaked at $12.4K in Q2 2024.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.